Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Rang în acțiuni #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Preț acțiune
$58.70
Ultima sincronizare: 2024-01-23
Capitalizare de piață
$2.98B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Mirati Therapeutics, Inc. (MRTX)

Categorie

Raport P/B pentru Mirati Therapeutics, Inc. (MRTX)
Raport P/B la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Mirati Therapeutics, Inc., raportul P/B actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/B de 0.
Istoricul raportului P/B pentru Mirati Therapeutics, Inc. din 2026 până în 2026
Raport P/B la sfârșitul fiecărui an
An Raport P/B Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raport P/B pentru companii similare sau competitoare
Companie Raport P/B Diferență raport P/B Țara
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH